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INTRODUCTION 
 
 Tuberculosis, an ancient disease, continues to remain even today as a major 
public health problem in much of the developing countries like India.  
 
 The Problem is now complicated by relentless spread of Human 
Immunodeficiency virus (HIV) which  causes Acquired Immunodeficiency 
syndrome (AIDS) pandemic and the emergence of multi drug resistant strains.  
 
 Infection with HIV results in progressive immunodeficiency and renders the 
infected person become increasingly vulnerable to wide range of pathogens. In 
many parts of the world Tuberculosis is the most common opportunistic infection 
in HIV infected person. The immune defects produced by HIV influence the 
natural course of TB infection.  
 
 Thus the HIV pandemic has altered both the epidemiology of TB and 
measures for approaches to its control. In populations where the risk of TB and 
HIV infections are high, the incidence of TB is expected to increase particularly in 
countries like India. 
 
 In this study, an attempt has been made to study the Clinical Spectrum, 
laboratory and radiological changes in patients having pulmonary TB in HIV 
Patients. 
    
AIMS OF THE STUDY 
 
1. To study the clinical spectrum of pulmonary TB and HIV patients attending 
our Medical college Hospital. (both inpatients and outpatients). 
 
2. To study the laboratory and radiological changes in the above said patients.  
 
3. To evaluate the diagnostic limitations of tuberculin test and sputum smear 
microscopy for AFB in patients having tuberculosis infection in HIV.  
HISTORY 
 
HISTORY OF TUBERCULOSIS  
 
 Evidence of TB has been found in the bones of prehistoric man in Germany, 
dating back to 2000 B.C. Also typical TB changes have been found in spines of 
skeleton of ancient Egyptian. (2500 to 1000 B.C) 
 
 Hippocrates  also devoted some attention to this. Aristotle conceived the 
theory that TB is an infectious diseases. Villerriun in 1865 showed in a series of 
classical experiments that TB is caused by a specific agent that can be transmitted 
from man to animals by inoculation of infected material. Robert koch applied 
himself and in 1882 the elusive microbe was identified. 
 
 The discoveries of stethoscope by Laennec in 1819, and the works of 
Rudolph virchow the founder of the Cellular pathology, X ray, by Roentgen in 
1895, allergy coined by Von Priquet in 1907 and BCG by Calmette and Guerin 
(from 1908 to 1921) evolutioned the study of TB in Humans. 
HISTORY OF HIV  
 
 AIDS was first recognized in USA in 1981 by CDC. 
 
 In 1983 HIV Virus was isolated from a patient with lymphadenopathy and 
by 1984, it was demonstrated clearly to be the causative agent of AIDS. In 1985 
sensitive ELISA was developed to diagnose it. 
 
 In India HIV was first identified from a commercial sex worker in chennai 
in 1986.  
 
 Early in the course of Human immunodeficiency syndrome, the link 
between HIV and TB was not clearly recognized. During the past decade TB has 
became the major opportunistic infection complicating the HIV epidemic 
worldwide. 
 
 By the year 2000, the prevalence of HIV and TB continued to climb 
worldwide. In 2000, the Global programme on AIDS of the WHO estimated the 
prevalence of HIV infection among adults and children worldwide was 36.1 
million. At the same time about 2 billion people had latent infection with 
M.Tuberculosis and approximately 11.8 million people were co – infected. 
REVIEW OF LITERATURE 
 
EPIDEMIOLOGY  
 
 Mycobacterium Tuberculosis infects one third of the worlds population (i.e) 
about 1.9 billion people. Worldwide each year there are 8 million new cases of 
Tuberculosis with 3 million deaths. 
 
 This death comprise 25% of all available deaths in developing countries. 
95% of TB cases and 98% of Tuberculosis deaths occur in developing countries. 
Three fourth of the TB cases in developing countries occur among the 
economically productive age group.(i.e) 15 to 50 years of age. Rate of TB 
infection are highest where people are poor and over crowded. Much of the TB 
burden is in South East Asia. 
 
 According to WHO 39% of all notified cases globally are contributed by 
countries of South East Asia followed by Western Pacific (25%), Africa (15%), 
Eastern Mediterranean (4%), Americas (7%), and European Regions (10%).  
 
 In South East Asia 95% of TB cases are reported from India, Indonesia, 
Myanmar, Thailand while in western Pacific great majority are from China, 
Philippines, Vietnam, Cambodia. 
 The situation is likely to be further complicated by the rapidly spreading 
HIV pandemic. Of the five million adults with HIV infection in South East Asia 
region, 1.5 million are likely to be infected with TB. Given the annual risk of 
clinical Tuberculosis which varies from 5 to 8% among dually infected 
individuals, further increase is Tuberculosis incidence seem inevitable. 
 
 Rapid increase in Tuberculosis attributed primarily to HIV have already 
been noticed in USA as well as in countries of sub – saharan Africa.  
 
 The dual epidemic of TB and HIV is also a significant problem in the 
developed countries. For the first time since 1953, an increase of 2.5% in TB cases 
was reported from USA in 1986. 
 
 The incidence of TB in HIV infected patient is about a hundred fold than 
that in the general population. Even more dramatic is the effect seen when person 
who are already infected with HIV became newly infected with Mycobacterium 
Tuberculosis.  
 
 In two outbreaks in which HIV infected persons were exposed to cases of 
infectious Tuberculosis, 40% of infected persons developed active TB within a few 
months. In HIV infected persons active TB seems to develop soon after infection 
and progresses rapidly, often resulting in death. 
IMMUNOPATHOGENESIS OF TB IN HIV 
 
 The impact of HIV and TB infection is bidirectional (i.e) TB affects the 
natural history of HIV infection and HIV affects the presentation and natural 
history of TB. Substantial evidence exist that the consequence of HIV and TB 
infection are greater than would be the case for either condition singly. 
 
 A study from several Hospitals in USA examined the survival in a cohort of 
HIV infected patients who had been successfully treated for TB and compared the 
survival to a cohort of HIV infected person who had never had TB but were 
matched for CD4+ counts. At every level of CD4+ count survival in a Kaplan – 
Meier life table analysis was worse for patients who had TB than those who had 
not TB17. From this study TB accelerates the natural history of HIV infections and 
leads to earlier death.  
 
 Another study examined to the impact of concomitant TB in the course of 
HIV infection by comparing the HIV +ve patients with TB and without TB 
matched by CD4 counts. In this study TB was not an independent predictor of 
increased mortality but was associated with an increased risk of development 
opportunistic infections18. 
 
 More direct evidence of accelerated HIV progression from TB is provided 
by several invitro studies examining the interaction between the M.Tuberculosis 
and HIV at the molecular level. Zhang et al19. demonstrated that both cell wall 
components and whole M.Tuberculosis organisms increased the transcription of 
the long terminal repeat (LTR) of HIV invitro. This seems to be mediated through 
the activation of transcription factors nuclear factor KB (NF-KB) and IL – 6 The 
same investigator demonstrator this invivo by comparing HIV viral copies taken 
from bronchial alveolar lavage (BAL) samples from radiographically  abnormal 
areas of lungs of TB patients with those from normal segments and with samples 
taken from patients without TB.  
 
 Branched DNA levels of HIV were highest in samples taken from 
radiographically abnormal segments of lungs in HIV positive TB patients 
compared with controls. In addition branched DNA levels of HIV declined over 
time with TB treatment20.  
 
 
IMPACT OF HIV ON TB. 
  
CD4+ T lymphocytes and macrophages have a central role in the immune 
response to mycobacterial infections. HIV infections results in progressive 
depletion and dysfunction in CD4+ cells with defect in macrophages and monocyte 
function21. 
 As a result of this, HIV infected patients have an increased risk of 
reactivation of latent TB as well as increased risk of disease from new 
infection.6,22,23. In a prospective longitudinal study Guelar et al22 found a mean 
CD4+count of 77+ 103 cells / mm3 (range 1 to 400 cells / mm3) in 23 of 733 HIV 
infected PPD negative who ultimately developed TB. The mean CD4+of this above 
entire groups was 377 + 260 cells / mm3. 
 
 Macrophages based resistance against TB is due to its ability to control 
intracellular mycobacterial growth. CD4+ lymphocytes prime macrophages to 
control intracellular growth by releasing cytokines such as IF - γ, IL-1, IL-2 and 
TNF -α which activate blood born macrophages. An additional protective 
mechanism may be the generation of cytolytic T cells in response to 
mycobacteria24. CD4+ T cells and γ/δ T cells kill autologous infected 
macrophages25, 26. 
 
 Forte et al27 demonstrated decreased cytolytic T cell activity in HIV 
infected patients. The continued loss of CD4+ cells in HIV seropositive patients 
and their reduced production of IL-2 may be the causes of decreased cytolytic T 
cell activity28 . 
 
While the CD4+ cell decline over progressive HIV infection, the number of 
CD8+ cells and γ/δ T cell often increase29. Their role in the development of TB in 
HIV infected patients remains to be defined. 
IMPACT OF TB ON HIV  
 
 TB can accelerate the course of HIV infection17,30,31 Toosi et al32 
demonstrated enhanced susceptibility of blood monocytes from patients with TB to 
produce infection with HIV-1. As noted previously, infection with M.Tuberculosis 
stimulates release of mononuclear cytokines such as IL-1, IL-2, IL-6 and TNF-α. 
M.Tuberculosis upregulates genes for these cytokines33.  
 
These cytokines enhance replication of HIV-1 invitro using several lines34 
the mechanism of this stimulation has been localized to the 5’LTR of HIV–1; more 
specifically to the NF-KB transcription enhancer site35. Recently Zhang et al19 
demonstrated that M.Tuberculosis and its major antigenic cell wall component 
Lipoarobinomannan were potent inducers of HIV-1 replication and LTR 
transcription via nuclear factor NF-KB and IL–6 sites. This was through direct and 
indirect stimulation by the cytokines IL –1 and TNF-α. These data suggest that the 
cytokines involve in the defense against TB may be deleterious in HIV 
seropositive patients. The interaction between HIV and TB may increase viral 
burden accelerating progression to advanced stage of HIV disease36. 
 
 There is also a major impact of HIV infection on the natural history of TB. 
The major defect in immune function in patients with HIV infection is related 
mainly though not entirely to the decline in numbers and impairment of function of 
CD4+ T cells. These now substantial evidence from studies in human that CD4+ T 
Cell are of crucial importance in initiating and maintaining an effective host 
immune response against TB. 
 
 CD4+ T cells are classified in to atleast two types namely TH1 and TH2 
cells. TH1 and TH2  had different phenotypes based on the patterns of cytokines 
which they secrete37. TH1 cells primarily secrete IFN-γ whereas TH2 cells secrete 
IL-4, IL-5 and IL-10. It had been previously shown that a TH1 type response 
represented a favourable immune response in patients with Leprosy as compared 
TH2 response in the same disease.  
 
 Yamamura et al38 took biopsy specimens from Tuberculoid Leprosy lesions 
(Paucibacillary lesions without a great deal of tissue necrosis) and compared 
cytokines gene expression patterns with those seen in specimens from 
Lepromatous leprosy lesion (multibacillary lesion with extensive tissue necrosis). 
 
 In the tuberculoid lesions the inflammatory infiltrate consists of T 
lymphocytes with high levels of mRNA transcription for IFN - γ, IL-1. By 
contrast, in lepromatous lesions, the infiltrate is characterized by T cells with high 
levels of m RNA transcripts for IL–4, IL-5, and IL–10. These findings suggested 
that a TH1 type response is beneficial in response to infectious diseases.  
 
 Direct evidence of the beneficial nature of a TH1 type response in TB comes 
from studies by Condos et al39 who examined local immune responses in the lungs 
of patients with active pulmonary-TB. In patients with radiographically and 
clinically minimal diseases (i.e Noncavitory infiltrates and sputum samples that 
were negative for AFB on smear), there was a lymphocytic alveolitis characterized 
by cells that produced locally high amounts of IFN-γ. In contrast,  patients with 
advanced cavitory smear positive TB did not produce high levels of IFN - γ. 
 
 The significance of IFN - γ was further demonstrated by the same groups of 
investigators, who showed that exogenously administered IFN - γ had beneficial 
effects in patients with MDR TB40. These clinical studies support a large number 
of invitro and animal studies that also demonstrate an important role for IFN - γ is 
host defense against TB. These studies have established that this proinflammatory 
cytokine has several effects at the cellular level that are important in host defense 
against intracellular pathogens. This includes activation of alveolar macrophages 
leading to the production of reactive oxygen and nitrogen species considered 
important in growth inhibition and killing of M.Tuberculosis, increased expression 
of major HLA Complex class II and increased migration of lymphocytes. 
 
 As CD4+ cells are the major source of IFN γ and CD4+ cell count and 
function are depressed in patients with HIV infection, it stands to reason from the 
foregoing discussion that HIV infected persons would be especially susceptible to 
TB infection and disease.  
  
TUBERCULIN SKIN REACTIVITY  
 
Tuberculin skin reactivity is dependent on lymphokines release. The 
Tuberculin skin test is a delayed type hypersensitivity reaction that generally 
parallels cellular immunity. 
 
 Anergy, which develops as a consequence of progressive HIV infection 
undermines effort to detect occult TB infection in those who are greatest risk for 
active disease.  Johnson et al41 demonstrated that among patients with active TB, 
approximately 30% of those who were HIV seropositive and more than 60% of 
those with AIDS had tuberculin skin reaction to 5-Tu comprising less than 10mm 
of induration. 
 
 Similarly Heubner et al42 found that anergy was four times and 15 times as 
likely for persons with CD4+ counts of 200 to 400 cells / mm3  and less than 200 
cells / mm3 respectively as for persons with more than 499 CD4+  cells / mm3. 
However 40% of patients with counts less than 200 cells/mm3  were not anergic, 
suggesting that a CD4 cut off for assuming anergy could be misleading. 
 
Because of increased anergy, reactions of 5 mm of induration or larger are 
considered positive. 
  
Graham et al43  showed that skin test positivity varied markedly between 
HIV positive (14%) and HIV negative (25%)  patients, suggesting a cut off 
definition of 2mm of induration or more in HIV positive patients.  
 
In contrast Heubner et al44 found that small (1 to 4mm) tuberculin skin test 
reaction in HIV infected patients did not represent diminished reactivity due to 
HIV. They concluded that individuals who react to other delayed type 
hypersensitivity antigen should also mount a significant reaction ( >  5mm) to  
tuberculin if they are truly infected with M.Tuberculosis. Any test in a HIV 
positive persons with a reaction of 5mm or greater should be considered positive. 
 
CLINICAL PRESENTATION  
 
 Pulmonary involvement occurs in atleast 75% of all HIV infected patients 
with TB. Symptoms and physical findings are usually not predictive of TB in HIV 
seropositive patients.  
 Unfortunately fever, sweats, fatigue, weight loss, anorexia and cough are 
very common symptoms in HIV seropositive patients and are suggestive of 
diseases such as Pneumocystis pneumonia, Histoplasmosis, Lymphoma wasting 
syndrome and MAC infection. 
 
 M.Tuberculosis is now regarded as the most common cause of fever of 
unknown origin in HIV infected patients. Modilevsky et al50 found fever (91%) 
and cough (84%) to be the most common presenting symptom in a retropective 
study of 39 patients in Los Angeles. Other symptoms included a mean weight loss 
of 11+ 3.2kg, dyspnoea (64%), chest pain (25%), as well as extra pulmonary 
symptoms such as diorrhoea (54%) and abdominal pain (26%). On physical 
examination the mean temperature was 39.2 + 0.80C and tachypnea was observed 
in only 36% of patients.  
 
 In a study by Soumya Swaminathan et al3 the distribution of symptoms 
were cough (97%), weight loss (94%), fever (79%), dyspnea (68%), chest pain 
(47%), and hemoptysis (18%). The distribution of clinical signs were muscle 
wasting (47%), Oral thrush (38%), Lymphadenopathy (29%), Clubbing (18%), 
Pedal oedema (9%), Bronchial breathing (14%), Rhonchi (14%), Crepitations 
(55%).         
    
   In Tambaram study2 the symptoms were Cough (85.43%), Fever (63.06), 
Dyspnoea (61.31%), Odynophagia (60.44%), Anorexia (51.44%), Weight loss 
(49.69%), Diarrhoea (33.81%), Chest Pain (19.81%), Fever with rigor (18.00%), 
Haemoptysis (11.50%).  The physical signs were Tamabaram Tongue (87.93%), 
Nail changes (52.63%), Clubbing (46.00%), Respiratory distress (42.94), Oral 
thrush (40.81%), Wasting (36.13%), Jaundice (18.81%), Genital ulcers (18.50%), 
Skin lesions (17.13%), CNS manifestations (13.63%) and Herpes Zoster (11.81%). 
 
 Because signs and symptoms are so non-specific, tuberculin skin testing 
could be a useful part of the clinical evaluation. However more than 50% of 
patients with active TB and another AIDS defining diagnosis are anergic8,9,41 . 
Negative PPD results and anergy were more common with increasing 
immunodeficiency as measured by CD4+ counts.  
 
 Markers of severity such as mycobacterimia and positive AFB smears were 
more common in patients with markedly depressed CD4+ cells counts, according 
to Jones et al49.  
 
 In contrast tuberculous pleuritis and positive tuberculin skin test results, 
which are dependent on the integrity of cellular immunity were more common in 
patients with higher CD4+ cell counts. In most industrialized countries, the clinical 
features of TB vary according to the degree of immunosuppression and atypical 
presentation are more commonly found among the immunosuppressed patients. 
This may not be true for extrapulmonary TB5. 
 
 In sub-Saharan Africa, patients with HIV related TB are more likely to 
present with extrapulmonary disease, miliary infiltrates, and non reactive 
tuberculin test responses than are those without HIV infection11-14,15,16,51 .  African 
studies have provided clinical correlation with CD4+ cell counts. Whether patients 
who have been reported in African series were more immunosuppressed is 
unknown.  
 
RADIOLOGICAL FINDINGS  
 
 The spectrum of radiological findings of TB in HIV infected patients is 
similar to that observed in seronagative patients. A compilation of reported 
radiologic findings from 15 studies involving 457 HIV positive patients in USA 
revealed that more than 30% patients presented with hilar or mediastinal 
adenopathy6,8-10,45-49,52-55. Cavitation was present in only 18% of patients, while 
apical or upper lobe infiltrates were seen in slightly more than 25%. Lower lobe 
infiltrates (10%), diffuse or miliary patterns (7%) and pleural effusions (17%) were 
also observed. Normal appearing chest radiographs were found in 6% of patients 
with proved TB. However these tactics are misleading. As with clinical findings 
radiographic manifestations appear to correlate with the degree of 
immunosuppression.  
 
 In Tambaram study2 the radiological patterns of pulmonary tuberculosis in 
seropositive TB patients are as follows.  
 
Upper zones   - Exudative -  34.80% 
    Nodular - 23.69% 
    Fibrotic  - 21.98% 
    Cavities - 17.21% 
 
Mid & lower zones - Exudative -  41.58% 
    Nodular - 26.53% 
    Fibrotic  - 7.60% 
    Cavities - 7.08% 
 
 All zones   - Miliary - 5.14% 
 
 In a study by Soumya Swaminathan et al3 the Radiological lesions at 
presentation were Normal X-ray - 9%, Pleural effusion - 12%, Mediastinal glands - 
3%, Pneumothorax - 2%, Opacities in Focal U/L, Focal L/L, Extensive were  
9%,14%, and 38% respectively. Cavation U/L - 11%, L/L - 3% and Miliary 
tuberculosis - 17% were also reported.    
 Greenberg et al52 , correlated radiographic findings with CD4+  cell counts 
in 68 patients. 55% of patients with CD4+ cell counts greater than 200/mm3 
showed a typical post primary pattern compared with only 23% of those with  
CD4+ cell counts with less than 200 /mm3.  
 
Jones et al49 found mediastinal adeopathy in 21of 58 patients [30% with 
fewer than 200 CD4+ cell / mm3 compared with only four (13%)of patients with 
more than 200 CD4+ cell / mm3]. In contrast pleural effusion were present in 6 of 
58 (10%) patients with CD4+ cell less than 200 /mm3 verses 8 (27%) of 30 patients 
with more than 200 cells / mm3. 
 
Thus HIV seropositive patients with less immunosuppression (i.e higher 
CD4+ cell counts) often have radiographic findings typical for reactivation. These 
include infiltrates in the posterior segment of upper lobes and superior segment of 
lower lobes. Cavitation may be present.  
 
As immunosuppression increases with falling CD4+ cell counts,  “atypical” 
findings occur more frequently. Infiltrates can be focal, occurring in the middle 
and lower lobes more frequently or can be diffuse, reticular, nodular or even 
miliary. Upper lobe infiltrates and cavitation are unusual. Chest radiography may 
also appear normal in 7% to 14% of patients52,56 . The clinician must maintain a 
high index of suspicion for TB in a patient who present with cough and sputum 
production but a normal appearing chest radiograph57.     
 
Unilateral and bilateral pleural effusion occur with varying frequency 
ranging from 10% to 38 % 8-10,46,48,49,52,56,58. In a series from USA 44 to 50% had 
associated infiltrates and 5% to 20% presented with hilar and or mediastinal 
adenopathy. Effusions were bilateral in 10% to 28% of patients59,60. Similarly 
Batungwanayo et al61, in a study of HIV related Tuberculous effusions in Kigali, 
Rwanda found associated localized infiltrates (28%), miliary patterns (14%) and 
adenopathy (11%) in 57 patients with AIDS. 
 
Richter et al62 , in a prospective study of HIV seropositive patients with 
tuberculous effusions in Dar es Salaam, Tanzania reported that one third of the 
patients had evidence of disseminated tuberculosis disease.          
 
Radionucleotide studies are not routinely performed in patients with TB. 
However in the workup of AIDS patients presenting with pulmonary 
complications, Gallium scans have proved useful in distinguishing different 
manifestations63. TB and lymphoma commonly show focal uptake in the hilar, 
mediastinal and lung parenchyma.Thallium shows high affinity for certain tumours 
such as Kaposi sarcoma and lymphoma.  
 
Lee et al64 have demonstrated that sequential thallium – gallium scans 
display a focal mismatch that is specific for mycobacterial infections though 
fungal disease due to Cryptococcosis, Histoplasmosis and Coccidiodomycosis 
cannot be excluded.         
 
     The role of CT of the chest is limited because findings are usually 
nonspecific. However subtle abnormalities like miliary pattern or unusual 
cavitation may be found and  highly characteristic finding is the presence of low 
density hilar and mediastianal nodes. Peripheral enhancement of enlarged nodes is 
observed following the intravenous administration of contrast material. The low 
density areas located centrally within the nodes are presumably due to caseation or 
liquefaction necrosis.  
 
DIAGNOSIS 
 
SPUTUM FOR ACID FAST BACILLI 
  
It is estimated that sputum AFB smears are positive in 65% to 75% of HIV 
seronegative patients who have had multiple specimens and in 30% to 40% of 
those with a single specimen66-68. In a non HIV setting Kim et al66 found positive 
smears in 20% to 40% of patients with minimal diseases, in 60% to 70% of 
patients with moderate disease and 90% to 95% of patients with advanced cavitary 
disease. Similarly Greenbaum et al reported68 positive smears in 52% of patients 
with cavitary disease but in only 32% of patients with local infiltrates.  
 
Barnes et al69 found positive smears in 90% of patients with radiographic 
findings typical of adult reactivation and for 98% of patients with cavitary TB, 
AFB was found on sputum smear. 
  
In a study by Soumya Swaminathan et al3, of the 65 cases who had culture 
confirmed pulmonary tuberculosis, 83% were smear positive at intake. In 
Tambaram study2, of the total 1600 having tuberculosis and HIV disease, just 235 
patients (15%) were sputum positive.  
 
SPUTUM CULTURE  
 
 It remains the gold – standard for diagnosis of pulmonary Tuberculosis. In 
resource poor countries, the diagnosis is heavily dependent on the sputum AFB 
smears.  
 
 HIV positive patients have been reported to have a lower yield in AFB 
smears. Brindle et al70, measured the concentration of viable tubercle bacilli in 
sputum. HIV patients excreted slightly fewer organisms per ml of sputum than did 
HIV negative patients with culture confirmed Tuberculosis. Positive AFB smears 
were observed in 31% to 89% of patients; culture were positive in 85% to 100% of 
patients. 
 
 Kleen et al71, found that only 11 of   38 patients (29%) with AIDS or AIDS 
related complex had an initial positive smear compared with 35 of 57 control 
patients (61%).  
 
 Repeated sputum samples (up to 5) brought the yield to 45%. In a study by 
Kramer et al7 analyising the reasons for delayed diagnosis of TB, the most frequent 
problem was that too few (fewer than 3) sputum samples were obtained for 
mycobacterial study in patients with respiratory symptoms and radiographic 
findings suggestive of TB.  
 
 The sensitivity of sputum smears may be greater in patients with less 
immunosuppression because they present with X-ray picture typical of 
reactivation. Close to 90% of patients with pulmonary TB have an abnormal chest 
radiographs where as up to 10% have a normal chest radiograph. Findings of 
classic TB such as apical infiltrates and cavitation are less common in HIV 
infected patients; and lower lung disease is more common as are 
lymphadenopathy, pleural effusions and interstitial infiltrates. 
FIBROOPTTIC BRONCHOSCOPY       
  
It is a useful means of making a rapid diagnosis of TB in selective patients. 
Miro et al72 studied 27 high risk patients for HIV infections.  Positive AFB smears 
were found in the sputum, BAL fluid and / or bronchial washings in 30% of 
patients, compared with a 37% positive yield form bronchial brushings and /or 
transbronchial biopsy specimens (p value not significant). The addition of the 
transbronchial biopsy specimen increased the culture yield from 96% to 100% (p 
value not significant). They concluded that transbronchial biopsy did not 
contribute significantly to the diagnosis of TB.  
 
In contrast, in a retrospective study, Kennedy et al73 found that 
transbronchial biopsy provided the exclusive means for rapid diagnosis in 6 of 59 
patients by demonstrating granuloma. BAL provided the diagnosis in 7 of 60 
patients exclusively. 
 
Transbronchial needle biopsy of mediastinal adenopathy has also proved 
useful for diagnosing TB in otherwise sputum negative and bronchoscopy negative 
patients74. When bronchoscopy is performed, the appropriate infection control 
practices for both HIV and TB must be followed.  
POLYMERISE CHAIN REACTION                
 
 The diagnostic approach that has elicited most excitement recently is PCR. 
Diagnostic PCR is a DNA amplification technique that utilizes specific DNA 
sequences to serve as the marker for the presence of the organisms. Theoretically 
PCR may detect fewer than 10 organisms in a specimen in contrast to the 10,000 
organisms per ml necessary for sputum AFB positivity.  
 
 In studies by Walker et al75 and Schluger et al76, they found that PCR has 
higher sensitivity but only lower specificity. It has sensitivity of 100% but 
specificity of only 70%. 
 
 Because of the limited clinical experience, as well as its cost and technical 
expertise, routine use of PCR cannot be recommended although this is 
unquestionably true that this technique represents its superiority over AFB smears 
in previously untreated TB patients71. 
 
 Regarding the pleural specimens, only the percentages for AFB on pleural 
tissue and AFB cultures were statistically greater in HIV positive patients than 
HIV negative patients59. 
 
 Although most common practice prior to AIDS epidemic, blood culturing 
for mycobacterial growth is routine in HIV infected patients, the frequency of 
positive blood cultures were inversely proportional to the CD4+ cell counts. Jones 
et al49 found that blood cultures were the only extra pulmonary source of 
M.Tuberculosis in 13 of 43 patients with no more than 100 CD4+ cell counts. 
 
EXTRA PULMONARY TUBERCULOSIS IN HIV 
PATIENTS  
 
 Since 1987 extrapulmonary TB has been has accepted as an AIDS defining 
diagnosis. The frequency may be related to the degree of immunosuppression as 
well as to the extend of diagnostic assessment49,78. The frequency of 
extrapulmonary TB ranged from 25% to 66%. 
 
 The common presentation are as disseminated TB (blood, bonemarrow or 
liver), TB of genitourinary tract, peripheral lymphnodes, pleura, central nervous 
system and abdomen including nodes in peritoneum and mediastinum. 
 
 Dissemination was categorized either as miliary TB (miliary pattern on X-
ray, or miliary lesion in liver, bonemarrow biopsy or autopsy) or focal 
disseminated (concurrent involvement of atleast 2 noncontiguous organ sites.) 
 
 Not all studies found a progressive increase in the frequency of extra 
pulmonary TB with decreasing CD4+ cell counts. Certain studies like Llibre et al79 
indicates the above statement. 
 
 Certain studies like above one, cervical lymphadenopathy was the most 
common extrapulmonary site. Lymphadenopathy either intrathoracic or 
extrathoracic is the most common extrapulmonary  manifestation. 
 
 In patients with extrapulmonary TB, normal appearing chest radiographs 
are found in 10 to 15% of patients, which is similar to non  HIV patients. 
 
 Regarding the AFB in stool, it was found to be positive in about 40% of 
patients with TB in HIV50. This probably represents organisms in swallowed 
sputum, since these patients have positive sputum smears and rarely exhibit 
gastrointestinal TB. 
 
 An unusual extrapulmonary manifestation is the formation of TB abscess in 
atypical location, like in neck, mediastinum, liver, abdominal wall, pancreas, and 
psoas muscle. 
 
MULTI DRUG RESISTANT TB IN HIV 
 
 
 HIV infected patients more likely to acquire TB when exposed to other 
patients with TB. 
 
 Recently several outbreaks of MDR-TB in HIV were reported, indicating 
the rapid emergence of MDR-TB in HIV.  
 
 Factors that have led to these MDR-TB outbreaks are multiple. They are as 
follows :  
(i) Increased transmission of MDR-TB to other HIV patients. 
(ii) Delay in the diagnosis and treatment of TB in HIV. 
(iii) Failure to achieve full compliance because of poor physical condition of the 
patient especially in countries like India, Sub-Saharan African countries. 
(iv) Failure to recognise drug resistance and many more.] 
 
TREATMENT           
 
 Centres for disease control (CDC) advisory panel has revised 
recommendations for treatment of tuberculosis in HIV infected patients.  Based on 
the substantial potential benefit of highly active, antiretroviral therapy (HAART) 
and availability of numerous drugs active against HIV, withholding antiretroviral 
therapy until completion of therapy for tuberculosis is no longer recommended.  
 
 The currently recommended regimens provided three options for treatment 
of Tuberculosis in HIV infected patients. The guiding principles of these options 
are  
(i) that Antiretroviral therapy should be administered when indicated,  
(ii) that a short course regimen (treatment course of 6 to 9 months 
depending on the regimen), administered as directly observed therapy is 
preferred in treatment of tuberculosis because of improved compliance 
and 
(iii) Because of its more favourable drug interaction profile, Rifabutin is 
preferred over Rifampin.  
 
Rifampin is contraindicated for use with Protease inhibitors and non-
nucleoside reverse transcriptase inhibitas (eg. Nevirapine, Delaviridine) because it 
is a potent inducer of cytochrome P-450 enzyme system that metabolises these 
drugs and thereby decreases concentrations of these antiretroviral agents to sub 
therapeutic levels.  
 
    Rifabutin is a less potent inducer of cytochrome P-450 enzymes and 
therefore has less of an effect on Protease inhibitor concentrations. Rifabutin is 
also substrate for cytochrome P-450 enzymes which protease inhibitors inhibit 
leading to accumulation of Rifabutin to potentially toxic levels. This interaction 
however permits lowering the dose of Rifabutin, which in turn has less of an effect 
on protease inhibitors levels.  
 Drugs interaction between Rifabutin and Ritonavir, hard gel Saquinavir or 
Delaviridine are significant. Therefore use of any Rifamycins with these agent is 
contraindicated or not recommended. 
 
 Nucleoside reverse transcriptase inhibitors have no important interaction 
with Rifamycins and they may be used. Like wise, antituberculous medications 
other than the Rifamycins have no significant interaction with any nucleoside or 
non nucleoside reverse transcriptase  inhibitors or protease inhibitors and may be 
used. 
 
 If a protease inhibitors or non nucleoside reverse transcriptase inhibitors is 
to be started after giving Rifampicin, then atleast 2 weeks should elapse after the 
last does of Rifampicins. This time gape is necessary for reduction the enzyme 
inducing activity of Rifampicins prior to commencement of ARV. 
 
ATT FOR PATIENTS ON  ARV      
  
If a patients already on ART develops active TB, then the ART should be 
suitably modified to be compatible with RNTCP regimens. Treatment of TB 
patients co infected with HIV cannot be envisaged without Rifampin. In TB 
patients co infected with HIV, treatment should be first administered for TB under 
the DOTS regimens and if the patients clinical condition allow, ART should be 
started after completion of TB treatment. In patients with very low CD4+ cell 
count, requiring concomitant administration of ART and ATT, the ARV regimen 
should be modified by replacing Nevirapine with Efavirenz. On completion of TB 
treatment such patients can be switched back to Nevirapine. 
 
 Efavirenz is contraindicated in pregnant women due to its teratogenicity. 
Rifampicin reduces the drug exposure to Nevirapine and dose adjustment for 
Nevirapine co-administered with Rifampicin has not been established.  
 
 Options for treatment of TB in HIV infected patients who are receiving 
Antiretro viral therapy1 are as follows :  
 
OPTION – I 
 
1. INH 300mg + RBT 150mg + PZA 25mg / kg + EMB 15mg / kg daily 
for 2 months.  
2. Then INH + RBT daily at the same doses for 4 months or INH 900 mg + 
RBT 300mg twice weekly for 4 months.  
3. Do not use Ritonovir, Hardgel saquinavir, or Delaviridine for 
Antiretroviral therapy.  
 
OPTION – II   
 
 
1. INH 300mg + PZA 25mg / kg + EMB 15mg / kg + SM 15mg / kg (1g) 
daily for 2 months then 
2. INH 300mg + PZA 25mg / kg + SM 25 to 30mg / kg (1.5g) two to three 
times a week for 7 months.  
 
OPTION – III+ 
 
1. INH 300mg + RIF 600mg + PZA 25mg /kg + EMB 15mg / kg daily for 
2 months then  
2. INH 300mg + RIF 600mg daily for 4 months or INH 900mg + RIF 
600mg thrice weekly for 4 months. 
3. This regimen should be reserved for patients who either are                     
not receiving Antiretroviraltherapy or who are receiving 
Antiretroviraltherapy consisting only of Nucleoside reverse transcriptase 
inhibitors.  
 
¾ The dose of Rifabutin is 300mg daily if the patients is not taking a 
protease inhibitor or a non – nucleoside reverse transcriptase inhibitors. 
 
+ - Alternatively INH + RIF + PZA + EMB may be administered as a thrice 
weekly regimen for 6 months. 
 
In general, anti TB treatment is the same for HIV infected person as it is for 
others and all patients should be treated with RNTCP regimen under the DOTS 
strategy.  
 
All new TB cases known to be HIV positive should be treated with   
category – I regimen since they are more likely to be seriously ill. The retreatment 
cases are to be treated with category – II regimen. RNTCP regimens if supervised 
properly are as effective in HIV positive patients as in HIV negative patients.  
 
TB in patients who are infected by a strain that is resistant only to INH 
should be treated with < 3 drug regimen or RIF, PZA and EMB for the duration of 
the entire period either as daily dosing or thrice weekly regimen for 6 to 9 months; 
but for atleast 6 months after conversion of culture / smear to negative.  
 
In cases of mono Rifampin resistant organism, they should receive INH, 
PZA, EMB and SM regimen (Option - II). Sputum culture and smear should be 
monitored monthly to document their conversion to negative. 
 
CHEMO PROPHYLAXIS FOR TUBERCULOSIS  
 
 Preventive therapy for TB (i.e. treatment for latent TB infection) reduces 
the risk of development of active TB disease in HIV infected individuals, although 
the durability of this effect may be limited by high rates of re-infection with TB in 
high TB burden countries like India. 
 
 WHO recommends TB preventive therapy if possible in areas where 
diagnostic testing such as X-ray chest, is available to exclude active TB disease 
and where PPD skin testing is feasible. INH therapy for 6 months in PPD skin 
reactors could be given after exclusion of active TB disease. 
 
 
 In India, however INH prophylaxis is not recommended due to  
(a) Difficulty in excluding active TB disease in those with HIV and 
TB co-infection. 
(b) as the burden of TB is high in India, chemoprophylaxis may not 
be able to prevent the re-infection. 
(c) widespread use of INH for chemoprophylaxis without a system to 
ensure adherence to treatment may contribute to further increase 
in INH resistance.  
(d) PPD skin test may not be feasible and  also not reliable in 
severely immunocompromised patients. 
 
BCG AND HIV              
 
WHO and UNICEF recommend that asymptomatic HIV infected children 
should receive BCG vaccination as per the immunisation policies, but should be 
withheld in a child having symptomatic HIV infection. BCG when given to a 
symptomatic  HIV positive children will lead to disseminated BCG disease4. 
 
MATERIALS AND METHODS 
 
 The study was conducted in the Antiretroviral therapy (ART) op in 
Government Mohan Kumaramangalam Medical College Hospital, Salem in 2005. 
 
INCLUSION CRITERIA  
 
1. Patients included in the age group between 12 and 60. 
2. Patients with CD4+ cells counts with less than or equal to 200 cells per  
mm3 ( < 200 ). 
3. Newly diagnosed cases of pulmonary TB in HIV patients. 
4. Both sputum positive and sputum negative with X-ray and clinical 
evidence of PTB in HIV positive patients. 
5. Patients having pulmonary manifestations only. 
 
EXCLUSION CRITERIA  
 
1. Patients with age group of < 12 and > 60. 
2. Patients with CD4+ cell counts more than 200 cells per mm3 ( > 200 ).   
3. Patients having only extrapulmonary manifestation like, pleural 
effusion, lymphadenopathy, Meningitis etc.  
4. Patients having chronic ailements like CRF, Diabetes Mellitus, CCF, 
Stroke etc. 
METHODS  
 
 In this study, the eligible patients attending both medicine OPD and ART 
OP were evaluated in the following way.  
 
(a) Detailed History taking. 
(b) Physical examination. 
(c) Laboratory examinations which includes complete hemogram, blood 
biochemistry, Sputum smears, X – ray chest, CD4+ cell count, Tuberculin 
test and LFT, if needed  USG abdomen and CT scan.    
 
The details are collected in a Proforma. 
PROFORMA 
 
NAME :  AGE :  SEX :   OP/IP NO :  
F/H NAME :  OCCUPATION :  
INCOME  :  
ADDRESS  :  
SYMPTOMATOLOGY : 
COUGH  
SPUTUM    Quantity   Character   Smell 
HEMOPTYSIS  Yes   No 
    No of episodes  
    Amount 
BREATHLESSNESS 
    Dyspnoea  Grade 
WHEEZE    Yes   No 
CHEST PAIN  Yes   No 
FEVER   Continuous  Intermittent 
    Evening Rise of Temperature 
APPETITE 
WEIGHT LOSS  
ASSOCIATED SYMPTOMS :   Skin Lesion (Recent) 
Diarrhoea  
PAST HISTORY :  
H/O OF STD EXPOSURE   Pre-Marital    Extra-Marital  
Homo    Hetero 
No of Exposures  
H/O OF BLOOD TRANSFUSION  Yes    No  
      When   
H/O OF NEEDLE PRICK   Yes     No 
H/O OF DIABETES MELLITUS    
H/O OF HYPERTENSION  
H/O OF BRANCHIAL ASTHMA 
PERSONAL HISTORY  
Alcoholism   Smoker    Any other  
FAMILY HISTORY  : 
Spouse      Alive     Dead 
Cause  
When  
SOCIAL HISTORY  : 
Occupation  
TREATMENT HISTORY  : 
Drugs taken 
GENERAL EXAMINATION : 
Build  :           Nourishment : 
Anemia  Jaundice   Cyanosis      Clubbing            Weight 
LYMPH ADENOPATHY  : 
SKIN LESION  : 
GENITAL LESION  : 
RESPIRATORY SYSTEM : 
INSPECTION   : 
PALPATION  :  
PERCUSSION  : 
AUSCULTATION   : 
CVS  : 
ABDOMEN  : 
CNS  : 
INVESTIGATIONS 
BLOOD :  
 TC   DC   ESR   HB% 
URINE COMPLETE  : 
 Alb    Sugar    Puscells 
BLOOD SUGAR  : 
BLOOD UREA  : 
S.CREATININE   : 
S.ELECTROLYTES   : 
LFT : 
SPUTUM : 1. 
 2. 
 3. 
CXR PA VIEW  
 
 ECG   : 
 
USG ABDOMEN / CT  THORAX 
 
CD4+ CELL COUNT  : 
 
ABSOLUTE LYMPHOCYTE COUNT : 
Male
Female
RESULTS 
 
 The study group included 70 patients with CD4+ cell counts less than or 
equal to 200 cells per mm3 (< 200).  
 
SEX DISTRIBUTION 
 In 70 patients sex distribution was  
Table - 1 
Male 53 
Female 17 
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AGE DISTRIBUTIONS 
The age distributions were  
1. < 20  –  1 patients  
2. 21 to 40 –  48 patients  
3. 41 to 60 –  21 patients  
Table - 2 
Age No. of Patients 
< 20 1 
21 to 40 48 
41 to 60 21 
 
WEIGHT DISTRIBUTION 
The Weight distribution was given in the following table.  
 
Table – 3 
Weight in Kg. No.of patients 
Male 
No.of patients 
Female 
< 30 0 1 
31 to 40 3 11 
41 to 50 28 5 
> 50 22 0 
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SPUTUM AFB 
Sputum smear status was as follows  
Table – 4 
Sputum Smear  Status No. of patients 
Smear positive 25 
Smear Negative 45 
RADIOLOGICAL PATTERNS 
The radiological patterns were as in the following table.* 
 
Table – 5 
 
X-ray lesions No. of Patients Percentage 
Opacities / Infiltrates Focal 
upper zone  
10 14.28% 
Opacities / Infiltrates Mid 
and lower Zone  
24 34.28% 
Extensive Infiltrates 15 21.42 % 
Upper Zone Cavitations 7 10% 
Mid and Lowe Zone 
Cavitations 
15 21.42% 
Miliary Infiltrates  2 2.85% 
Pleural effusions  9 12.85% 
Mediastinal glands  7 10% 
Normal X-ray  5 7.14% 
 
*- 30 patients had more than one lesion.   
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CD4+ CELLS COUNT 
CD4+ cells count distribution was as shown in the following table. 
Table - 6 
CD4+ cells counts per mm3 No. of patients Percentage 
<  50 18 25.71 % 
51 to 100 22 31.42 % 
101 to 200 30 42.85 % 
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TUBERCULIN INDURATION 
The distribution was as follows : 
Table – 7 
Tuberculin induration 
(mm) 
No Percentage 
0 – 4 28 40% 
5 – 9 27 38.57% 
10 – 14 12 17.14% 
> 15 3 4.28% 
28
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ASSOCIATED CLINICAL FEATURES 
They are given as follows : 
Table - 6 
Clinical Features No. of patients 
Oral Thrush 24 
Nail Changes 18 
Cervical lymphnodes 9 
Diorrhoea 7 
Herpes labialis  (HS – 1) 2 
Herpes genitalis (HS – 2) 1 
Molluscum contagiousm 1 
 
24
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Nail Changes 
Cervical lymphnodes 
Diorrhoea
Herpes labialis  (HS – 1)
Herpes genitalis (HS – 2) 
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DISCUSSION 
 
TB is the commonest opportunistic infection in HIV positive persons in 
India and can develop at any stage of the HIV disease. 
 
Here we have studied the clinical and laboratory profile of TB in advanced 
stages of HIV disease. (CD4+ cells <   200 cells per mm3) 
 
 
AGE DISTRIBUTION  
 
The distribution of age group in the present study is  < 20 – 1 (about 1%), 
21 to 40 – 48 (about 70%), 41 to 60 – 21 patients (30%). In Tamabram  study2, age 
group distribution was < 20 – 3.19%, 21 to 40 – 74.9% and 41to 60 (20%). 
 
Hence the present study correlates nearly with the other studies in this 
respect.  
 
 
CLINICAL FEATURES   
 
 Of the 70 patients, most of the patients ( > 90%) with clinical features of 
cough with expectoration, fever, weight loss and dyspnoea. In a study by  
Modilevsky et al50,  the frequency of clinical symptoms were cough 84%, 
dyspnoea 64%, diorrheoa 54% and Chest pain 25% respectively. 
 In a study by Soumya Swaminathan et al3, the frequency of symptoms were 
cough 97%, weight loss 94%, fever 79%, dyspnoea 68%, chest pain 47% and 
hemoptysis 18% respectively.  
 
In our present study the distribution were cough 91% (64), fever 91% (64), 
dyspnoea 94% (66), hemoptysis 19% (13) and weight loss 95% (67).  
 
The differences may be attributed to study group variation.  
 
Oral thrush is found to be about 35% in our study. In a study by Soumya 
Swaminathan et al3, it was found to be 40% indicating the later stages of HIV 
disease. 
 
The mean duration of symptoms in our study is about 2 to 3 months. In the 
same study mentioned above3 the mean duration was 12 weeks. 
 
This indicates that there was a delay in the diagnosis and treatment of 
Tuberculosis. 
 
This delay may be at the patient level or at the health provider level.  
 
 
EXTRAPULMONARY MANIFESTATIONS          
 
 About 26% of patients had associated extrapulmonary manifestations          
(i.e pleural effusion, mediastional glands). This in comparison with a study by  
Soumya Swaminathan et al3, which showed that it was about 30%. Also various 
western studies like Jones et al49, Shafer et al78, revealing the range of 25 to 60%.  
 
SPUTUM SMEAR POSITIVITY    
  
 Smear positivity in present study is about 35% (25 of 70).  
 
 In a study by Deivanayagam et al2, it was 15%. In a study by Kleen et al71, 
it was found to be 29%. The increase in number of sputum samples will tend to 
increase the yield of smear positivity. In patients who were sputum smear negative, 
the diagnosis was made by assessing the clinico – radiological spectrum.  
RADIOLOGICAL PATTERNS  
 
 The radiological patterns were both typical and atypical presentation of 
pulmonary tuberculosis. 
 
But atypical presentations such as lower zone infiltrates and cavities, 
diffuse exudative infiltrates, pleural effusions and hilar / paratracheal adenopathy 
were more commonly observed.  
 
INFILTRATES  
 
In a study by Soumya Swaminathan et al3, the frequency were focal upper 
zone infiltrates – 9%, focal mid and lower zone infiltrates - 14% and extensive 
infiltrates - 38% respectively. 
 
 In Tambaram study2 they were found to 34.8%, 41.5% for upper zone and 
mid, lower zone infiltrates.   
 
In our study the distribution was focal upper zone infiltrates – 10 patients 
(nearly 15%). 
 
Focal lower and mid zone infiltrates – 24 patients (about 35%).    
Extensive infiltrates – 15 patients (about 21%). 
 
These differences may be attributable to the advanced stages of HIV disease 
in whom we had studied and also difference in the study group.  
 
CAVITARY LESION  
 
 In our study  focal upper zone cavity – 7 patients (10%) and mid / lower 
zone cavities – 15 patients (about 21%). In Tambaram study2 it was 17.2% and 
7.6% respectively. In Soumya Swaminathan et al3, the distribution was 11% and 
3% respectively. 
 
PLEURAL EFFUSIONS  
 
 In a study by Jones et al49, it was 10%, in Tambaram study2 it was 6.88% 
and in a study by Soumya Swaminathan et al3 it was 12%. In the present study the 
frequency of pleural effusions was about 14% (9 patients). 
 
NORMAL X-RAY 
 
 Here it was found to be in 5 patients (nearly 7 %). In western studies such 
as Greenberg et al52, Long R et al56, it was found to be present in 7 to 14% of study 
group and 9% of patients in the study by Soumya Sowinathan et al3.  
 This may be due to the diminished immune status in which there is a 
decreased or no inflammatory reaction occurring in the lung parenchyma. 
 
MILIARY TUBERCULOSIS  
 
 In our study it was present in 2 patients (3%), in a study by Batungwanoyo 
et al61 it was 14% where as it was 5% and 17% in Tambaram study2 and in a study 
by Soumya Swaminathan et al3 respectively. This variation may also attributable to 
the difference in the study group. 
 
MEDIASTINAL ADENOPATHY 
 
 The frequency of mediastinal adenopathy in studies by Jones et al49 was 
30% and in Batungwanoyo et al61 it was 11% and in Soumya Swaminathan et al3 
study it was 3% where as in our study it was present in 7 patients (10%)  
 
 
CD4+ CELL COUNT RANGE 
 
 The range of CD4+ cell count in our patients were < 50 – 18 patients   
(nearly 28%), 51 to 100 – 22 patients (nearly 31%) and 101 to 200 – 30 patients           
(nearly 41%) 
 In Soumya Swaminathan et al3 the mean CD4+ cell count was 192 cells per 
mm3 at base line.   
 
 
TUBERCULIN TEST 
 
 The distribution of indurations were 0 to 4mm – 28 patients (40%) 5 to 
9mm – 27 patients (38.57%), 10 to 14mm – 12 patients (17.14%), and more than 
or equal to 15mm – 3 patients (4.28%).  
 
 In Tambaram Study2  the distribution were 0 to 4 – 33.38%, 5 to 9 – 
18.62%, 10 to 14 – 22.06% and  > 15 – nearly 26%.  
 
In study by Soumya Swaminathan et al3, the distribution were 0 to 5mm -
56%, 6 to 10mm –3% and 11 to 20mm – 28% respectively.   
 
 This variation may be attributable to the difference in the study group 
population.  
CONCLUSION 
 
a) In our part of the world Tuberculosis is the common opportunistic infection 
even in advanced stages of HIV infection.  
 
b) It commonly affects male in the productive age groups (21 to 40). 
 
c) Most of the patients in advanced stages usually present with more than 3 of 
the 5 clinical features such as cough with expectoration, dyspnoea, fever, 
weight loss and hemoptysis.  
 
d) Oral thrush is present in about 35% patients which serves as an indicator of 
severity of disease (HIV infection) .   
 
e) Patients with Tuberculosis in HIV positive persons can present with normal 
X-ray even in advanced stages of HIV disease also. Hence presence of 
normal X-ray does not rule out the possibility of Tuberculosis in HIV 
patients.  
 
f) Patients in later stages of HIV infection usually present with atypical 
radiological patterns such as lower zone infiltrates, mid zone and lower 
zone cavities, pleural effusions, and hilar / paratracheal lymphadenopathy 
although classical upper zone infiltrates and cavities occur in less than 25 to 
30% of patients. 
 
g) Majority of the patients (42%) were in the CD4+ cell counts range of 100 to 
200 Cells / mm3. 
 
With the conventional sputum positivity and if Tuberculin test not providing an 
adequate diagnostic help, familiarity with the clinico – radiological spectrum of 
Tuberculosis is absolutely necessary.  
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EMC - Extra Maritial LT - Left
PMC - Pre Maritial B - Bilateral
EPI - Episodes UZ - I - Upper Zone Infiltrates
G - Grade LZ - I - Lower / Mid Zone Infiltrates
OC - Oral Candidias UZ - C - Upper Zone Cavity 
TV - Tenia Versicolor LZ - C - Lower / Mid Zone Cavity
NC - Nail Changes (Base pigmentatio, Ridges) ML - I - Miliary Infiltrates
D - Diorrhoea PE - Pleural Effusions
MPK - Maculo Papular Skin Lesion HSL - Herpes Labialis
J - Jaundice PRL - Paratracheal Lymphadenopathy
AG - Atrophic Glossitis PAL - Para Aortic Lymphadenopathy
CRLN, CL - Cervical Lymphadenopathy RPL - Retro Peritoneal Lymphadenopathy
PE - Pedal Edema HL - Hilar Adenopathy
KE - Kneejoint Effusion EXT - I - Extensive Infiltrates
GNLN, GL - Generalised Lymphadenopathy RT - Right
HG - Herpes Genitalis (I) - In patients 
WNL - Within normal limit
